AMEX:BPMX

Stock Analysis Report

Executive Summary

BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • BioPharmX has significant price volatility in the past 3 months.
  • BioPharmX is covered by less than 3 analysts.

Share Price & News

How has BioPharmX's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.6%

AMEX:BPMX

0.2%

US Pharmaceuticals

1.3%

US Market


1 Year Return

-92.5%

AMEX:BPMX

-7.3%

US Pharmaceuticals

2.0%

US Market

BPMX underperformed the Pharmaceuticals industry which returned -7.5% over the past year.

BPMX underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

BPMXIndustryMarket
7 Day-3.6%0.2%1.3%
30 Day13.8%1.2%3.9%
90 Day-57.0%-3.6%3.4%
1 Year-92.5%-92.5%-5.0%-7.3%4.2%2.0%
3 Year-97.8%-97.8%12.2%4.4%47.2%37.6%
5 Year-99.4%-99.4%21.1%8.1%60.5%42.9%

Price Volatility Vs. Market

How volatile is BioPharmX's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioPharmX undervalued based on future cash flows and its price relative to the stock market?

2.43x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for BioPharmX to establish if it is available at moderate discount.

Unable to calculate intrinsic value for BioPharmX to establish if it is available at substantial discount.


Price Based on Earnings

BioPharmX is loss making, we can't compare its value to the US Pharmaceuticals industry average.

BioPharmX is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BioPharmX, we can't assess if its growth is good value.


Price Based on Value of Assets

BioPharmX is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is BioPharmX expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-1.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BioPharmX's revenue is expected to grow significantly at over 20% yearly.

BioPharmX is not considered high growth as it is expected to be loss making for the next 1-3 years.

BioPharmX's revenue growth is expected to exceed the United States of America market average.

Unable to compare BioPharmX's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare BioPharmX's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if BioPharmX will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has BioPharmX performed over the past 5 years?

-4.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioPharmX does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare BioPharmX's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BioPharmX's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BioPharmX has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if BioPharmX has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if BioPharmX improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is BioPharmX's financial position?


Financial Position Analysis

BioPharmX is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioPharmX's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BioPharmX has no debt.

BioPharmX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

High level of physical assets or inventory.

BioPharmX has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BioPharmX has less than a year of cash runway based on current free cash flow.

BioPharmX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.5% each year.


Next Steps

Dividend

What is BioPharmX's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioPharmX's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioPharmX's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioPharmX has not reported any payouts.

Unable to verify if BioPharmX's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioPharmX has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BioPharmX's salary, the management and board of directors tenure and is there insider trading?

0.9yrs

Average management tenure


CEO

David Tierney (55yo)

1yrs

Tenure

US$1,397,992

Compensation

Dr. David S. Tierney, M.D. is a Director of Palvella Therapeutics, Inc. Dr. Tierney serves as Chief Executive Officer at BioPharmX Corp. since September 2018 and its President and Chief Financial Officer s ...


CEO Compensation Analysis

David's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for David to compare compensation growth.


Management Age and Tenure

0.9yrs

Average Tenure

The average tenure for the BioPharmX management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.7yrs

Average Tenure

65yo

Average Age

The tenure for the BioPharmX board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$334,42727 Jun 19
Vivo Capital, LLC
EntityCompany
Shares327,870
Max PriceUS$1.02
SellUS$12,74625 Jan 19
Anja Krammer
EntityIndividual
Shares4,634.96
Max PriceUS$2.75
SellUS$939,51407 Dec 18
Franklin Resources, Inc.
EntityCompany
Shares206,600
Max PriceUS$4.55
SellUS$83,42922 Oct 18
Stephen Morlock
EntityIndividual
Role
Member of the Board of Directors
Director
Shares17,563.96
Max PriceUS$4.75
SellUS$123,46722 Oct 18
Stephen Morlock
EntityIndividual
Role
Member of the Board of Directors
Director
Shares27,437.12
Max PriceUS$4.50
SellUS$95,00013 Oct 18
Anja Krammer
EntityIndividual
Shares20,000
Max PriceUS$4.75
BuyUS$20,25020 Sep 18
David Tierney
EntityIndividual
Role
Chief Executive Officer
President
Shares4,000
Max PriceUS$5.06

Ownership Breakdown


Management Team

  • David Tierney (55yo)

    President

    • Tenure: 1yrs
    • Compensation: US$1.40m
  • Steven Bosacki

    Chief Operating Officer

    • Tenure: 0.2yrs
  • Joyce Goto (45yo)

    VP, Chief Accounting Officer & Controller

    • Tenure: 0.9yrs

Board Members

  • David Tierney (55yo)

    President

    • Tenure: 1yrs
    • Compensation: US$1.40m
  • Lorraine Tafra

    Member of Medical Advisory Board

    • Tenure: 4.8yrs
  • Lee Shulman

    Chair of Medical Advisory Board

    • Tenure: 4.8yrs
  • Scott Karlan

    Member of Medical Advisory Board

    • Tenure: 4.8yrs
  • Neal Bhatia

    Co-Chair of Therapeutic Dermatology Advisory Board

    • Tenure: 3.6yrs
  • Joseph Hunstad

    Member of Medical Advisory Board

    • Tenure: 4.8yrs
  • Patricia Sulak

    Member of Medical Advisory Board

    • Tenure: 4.8yrs
  • Mike Hubbard (67yo)

    Chairman

    • Tenure: 3.3yrs
    • Compensation: US$129.50k
  • Stephen Morlock (65yo)

    Director

    • Tenure: 4.5yrs
    • Compensation: US$94.00k
  • Hilary Baldwin

    Co-Chair of Therapeutic Dermatology Advisory Board

    • Tenure: 3.6yrs

Company Information

BioPharmX Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioPharmX Corporation
  • Ticker: BPMX
  • Exchange: AMEX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.366m
  • Shares outstanding: 14.19m
  • Website: https://www.biopharmx.com

Number of Employees


Location

  • BioPharmX Corporation
  • 115 Nicholson Lane
  • San Jose
  • California
  • 95134
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BPMXAMEX (NYSE MKT LLC)YesCommon StockUSUSDJun 2011
BPC1DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2011

Biography

BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product ca ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:08
End of Day Share Price2019/09/13 00:00
Earnings2019/07/31
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.